Ezra Frech, Team Sanofi Athlete

Ezra Frech, Team Sanofi Athlete

Ezra Frech, Team Sanofi Athlete

We Never Settle

Celebrating Team Sanofi athletes and Sanofians on the road to Paris 2024 Olympic and Paralympic Games.

Our Latest News

Social Impact

July 18, 2024

Caring for Community & Planet: How Sanofi Is Improving Lives While Reducing Its Emissions

Shuang Yang, Scientist, China

Second quarter 2024 results

Second quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session.

Thursday July 25, 2024
14:30 - 16:00 CET (8:30am – 10am EST)

United by Purpose

Each of us plays a unique role in bringing our purpose to life.

Sanofi X Paris 2024

We’re proud to be premium partner of Paris 2024.

Science and sport aren’t that different. Just like athletes do, we overcome setbacks to keep moving forward, not just for ourselves, but for our patients, colleagues, families and friends.

About Us

Who We Are

We are an innovative global healthcare company.

Our Pipeline


Therapeutic areas


Compounds in clinical development


Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases

July 17, 2024
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
July 3, 2024
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
June 28, 2024
Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS
June 26, 2024
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM